PMID- 37855338
OWN - NLM
STAT- Publisher
LR  - 20231019
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2023 Oct 19
TI  - SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.
LID - 10.2174/0109298673251493231011192520 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, 
      primarily in highly developed Western societies. T2DM causes systemic 
      complications, such as atherosclerotic heart disease, ischemic stroke, peripheral 
      artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. 
      The growing number of T2DM patients and the treatment of long-term T2DM-related 
      complications pressurize and exhaust public healthcare systems. As a result, 
      strategies for combating T2DM and developing novel drugs are critical global 
      public health requirements. Aside from preventive measures, which are still the 
      most effective way to prevent T2DM, novel and highly effective therapies are 
      emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose 
      co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient 
      perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, 
      such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, 
      along with SGLT-1, is a member of the SGLT family of proteins that play a role in 
      glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is 
      only found in the kidney, specifically the proximal tubule, and is responsible 
      for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose 
      absorption, and consequently increases urinary glucose excretion, decreasing 
      blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately 
      alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated 
      chronic complications. This review aimed to provide a more detailed understanding 
      of the effects of SGLT2i responsible for the acute improvement in blood glucose 
      regulation, a prerequisite for T2DM-associated cardiovascular complications 
      control.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Lukic, Nikola
AU  - Lukic N
AUID- ORCID: 0000-0002-9727-0503
AD  - Department of Radiobiology and Molecular Genetics, VINCA Institute of Nuclear 
      Sciences - National Institute of the Republic of Serbia, University of Belgrade, 
      Belgrade, Serbia.
FAU - Macvanin, Mirjana T
AU  - Macvanin MT
AUID- ORCID: 0000-0003-2811-9428
AD  - Department of Radiobiology and Molecular Genetics, VINCA Institute of Nuclear 
      Sciences - National Institute of the Republic of Serbia, University of Belgrade, 
      Belgrade, Serbia.
FAU - Gluvic, Zoran
AU  - Gluvic Z
AUID- ORCID: 0000-0001-6371-6610
AD  - Clinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun 
      Clinical Hospital, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
FAU - Rizzo, Manfredi
AU  - Rizzo M
AUID- ORCID: 0000-0002-9549-8504
AD  - Department of Internal Medicine and Medical Specialties (DIMIS), Universita degli 
      Studi di Palermo (UNIPA), 90128 Palermo, Italy.
FAU - Radak, Djordje
AU  - Radak D
AD  - Serbian Academy of Art and Sciences, Euromedic Clinic, 11000, Belgrade, Serbia.
FAU - Suri, Jasjit S
AU  - Suri JS
AUID- ORCID: 0000-0001-6499-396X
AD  - AtheroPoint, Roseville, Roseville, CA 95661, USA.
FAU - Isenovic, Esma R
AU  - Isenovic ER
AUID- ORCID: 0000-0002-0012-2636
AD  - Department of Radiobiology and Molecular Genetics, VINCA Institute of Nuclear 
      Sciences - National Institute of the Republic of Serbia, University of Belgrade, 
      Belgrade, Serbia.
LA  - eng
PT  - Journal Article
DEP - 20231019
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
SB  - IM
OTO - NOTNLM
OT  - SGLT-2 inhibitors
OT  - cardiovascular complications
OT  - sodium-glucose transporter proteins
OT  - treatment
OT  - type 2 diabetes mellitus
EDAT- 2023/10/19 12:44
MHDA- 2023/10/19 12:44
CRDT- 2023/10/19 07:44
PHST- 2023/03/01 00:00 [received]
PHST- 2023/06/19 00:00 [revised]
PHST- 2023/08/17 00:00 [accepted]
PHST- 2023/10/19 12:44 [medline]
PHST- 2023/10/19 12:44 [pubmed]
PHST- 2023/10/19 07:44 [entrez]
AID - CMC-EPUB-135360 [pii]
AID - 10.2174/0109298673251493231011192520 [doi]
PST - aheadofprint
SO  - Curr Med Chem. 2023 Oct 19. doi: 10.2174/0109298673251493231011192520.